Abstract
Prospects of adjuvant RANKL inhibition in breast cancer?
Highlights
The maintenance of bone health has been a clinical challenge in breast cancer patients receiving adjuvant endocrine treatment
Denosumab is a monoclonal antibody directed against RANKL that has been approved for the treatment of both osteoporosis and bone metastases.[1]
An earlier study had shown a significant increase of 5.5% in bone mineral density (BMD) at the lumbar spine with denosumab in 252 women with nonmetastatic breast cancer receiving aromatase inhibitors,[2] this trial was not designed to assess fracture risk
Summary
The maintenance of bone health has been a clinical challenge in breast cancer patients receiving adjuvant endocrine treatment. Denosumab is a monoclonal antibody directed against RANKL that has been approved for the treatment of both osteoporosis and bone metastases.[1] an earlier study had shown a significant increase of 5.5% in bone mineral density (BMD) at the lumbar spine with denosumab in 252 women with nonmetastatic breast cancer receiving aromatase inhibitors,[2] this trial was not designed to assess fracture risk.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
